MedTrace Logo

Effects of BFR-training on Stem Cells and Immune Cells in Human Skeletal Muscle

NCT07569627 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-06

No results posted yet for this study

Summary

In this 3-year project, investigators will first measure stem cells (primary outcome) and immune cells (secondary outcome) in human skeletal muscle immediately after and 24 hour after the BFR-training. In the second and third year, the effect of β-NMN (vitamin B3 precursor) and antioxidant on the same outcomes after BFR-exercise will be assessed. The BFR-exercise in the study will consist of a 5 × 10-second sprinting with maximal voluntary efforts, 5 minutes after a BFR pre-conditioning to legs using pressurized cuffs. In Study 1 (1st year, N = 24, aged 20-30 year), a randomized crossover trial will be conducted to compare the efficacy of sprinting exercise using BFR pre-conditioning at 20 mmHg (control) or 180 mmHg (occlusion). Study 2 (2nd year, N = 24, aged 20-30 years) will be conducted to examine the effect of β-NMN supplementation on the aforementioned outcomes in human muscles using a randomized placebo-controlled crossover study design. Study 3 (third year, N = 24, aged 20-30 years) will be conducted to examine the effect of vitamin C on the same variables immediately after and 24 hours after resistance exercise intervention, using a randomized placebo-controlled crossover study design.

Conditions

  • Exercise
  • Blood Flow Restriction (BFR) Training Effects
  • Supplement

Interventions

BEHAVIORAL

BFR (180 mmHg)

Sprinting exercise after BFR

DIETARY_SUPPLEMENT

NMN-BFR exercise

NMN ingested before and after BFR exercise

DIETARY_SUPPLEMENT

Vitamin C-resistance exercise

Vitamin C ingested before and after resistance exercise

Sponsors & Collaborators

  • University of Taipei

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2025-05-01
Completion
2025-05-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07569627 on ClinicalTrials.gov